Personalized neoantigen vaccine & pembrolizumab in HCC
Nature Medicine
doi.org/10.1038/s41591…
🔎phs 1/2, 36 pts
👉Tumor-specific vaccine, 40 neoantigens
👉ORR 30%, 8% CR, mPFS 4.2 & mOS 19.9 mo
💪molecular correlates
🧐Looks promising..
ESMO - Eur. Oncology EASLnews ILCA #livertwitter

Pre-transplant Use of Immune Checkpoint Inhibitors for HCC
American Journal of Transplantation
doi.org/10.1016/j.ajt.…
🔎 RWD🇨🇳, 83 pts
👉27.7% developed allograft rejection, mortality: 6/83
👉≥ 30 days before TX protective
🤔feasible, but relevant risk
ESMO - Eur. Oncology ILCA EASLnews #livertwitter

Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients
👉🇨🇦lags far behind🇺🇸&🇪🇺
👉Clear demands to improve access to innovative therapies
CADTH Health Canada and PHAC: read carefully!👇

Prognostic & predictive impact of sex in locally advanced MSI gastric or gastroesophageal junction cancer
doi.org/10.1016/j.ejca…
🔎pooled analysis of 4 trials
👉MSI better than MSS
👉♀️MSS do better then ♂️MSS
👉Detrimental effects of CTx > in ♀️MSI then ♂️MSI
🧐Impact of sex in

❓How to best manage immune.related AEs
Impact of immunosuppressive agents on the
management of irAEs of immune checkpoint blockers
doi.org/10.1016/j.ejca…
👉Infliximab & Methotrexate: no impact on survival
👉Steroids alone: worse outcome
🧐Better early use of immunosuppressants?

Anti-EGFR Rechallenge in Refractory ctDNA RAS/BRAF wt mCRC
JAMA Network Open
doi.org/10.1001/jamane…
🔎🇮🇹CAVE, VELO, CRICKET, CHRONOS; 119 pts, ≥3rd line
👉DCR 72%, mPFS 4, mOS 13,1 mo
👉Worse outcome in pts w/ liver mets
🧐re-challenge feasible in RAS/BRAF wt
ESMO - Eur. Oncology

Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies
Science Magazine
doi.org/10.1126/scienc…
👉liver resident macrophages limit half-life of cfDNA
👉nanoparticles🚫clearance
😅Really cool & could help to boost sensitivity of ctDNA

Wonderful night in Toronto thanks Eisai Oncology Medical for the support! Celebrating Arndt Vogel University Health Network Princess Margaret Cancer Centre so much and so exciting things happening in #HCC and #CCA world! Laura Dawson Sean Cleary Erica Tsang Rob Beecroft TEAM WORK IS THE KEY TO SUCCESS! ⭐️

Clinical Benefit & Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval
JAMA
doi.org/10.1001/jama.2…
🤨Despite 5 yr follow-up, most cancer drugs granted accelerated approval did not demonstrate benefit in OS or QoL in confirmatory trials
ESMO - Eur. Oncology

Nivolumab in sorafenib-naive & sorafenib-experienced hepatocellular carcinoma: 5-yr follow-up from CheckMate 040
Annals of Oncology
doi.org/10.1016/j.anno…
👉ORR 20 & 14%
👉mOS 26.6 & 15.1 mo
👉5-yr (!) OS rates 14 & 12%
😅CheckMate 9DW awaited..
ESMO - Eur. Oncology EASLnews ILCA

FDA approved trastuzumab deruxtecan for previously treated unresectable or metastatic HER2-positive solid cancers
👉first tumor-agnostic approval for antibody-drug conjugate targeting HER2-positive tumors
👉More options for many GI-cancers, incl. CRC & BTC
ESMO - Eur. Oncology Cholangiocarcinoma Foundation

Physical activity & checkpoint inhibition: association
with toxicity & survival
JNCI
doi.org/10.1093/jnci/d…
🇩🇰 RWD, 251 pts
Higher physical activity levels at the start of ICI treatment:
👉 lower risk of severe irAEs
👉 probably longer survival
😅'easy' to implement

A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening
NEJM
doi.org/10.1056/NEJMoa…
👉ECLIPSE trial, Guardant Health assay, 7861 screened, 65 CRC
👉CRC pts: 83.1% cfDNA+; 16.9% cfDNA-
👉Non-CRC: 10.4% cfDNA+
🧐Additional tool for screening…
ESMO - Eur. Oncology

Prediction of Adjuvant Gemcitabine Sensitivity in #PDAC Using the GemPred RNA Signature:
Journal of Clinical Oncology
doi.org/10.1200/JCO.22…
👉GemPred includes >2,000 genes
👉Predictive for Gem, looks convincing
👉Similar efficacy with less tox compared to FOLFIRINOX
🧐We need prospective

ctDNA GA as a biomarker of OS for panitumumab in #CRC
Nature Medicine
doi.org/10.1038/s41591…
🔎PARADIGM
👉GA: KRAS, NRAS, PTEN, ED-EGF, HER2, MET, ALK, RET & NTRK1
👉Benefit for Pani in hyper selected pts
😅Biomarker guided in CRC…

Immunotherapy vs CTx in MSI non-colorectal digestive cancers
Oncology Advance
doi.org/10.1016/j.ejca…
👉133 pts, 1st 29%, 2nd line 44%
👉ORR: 26% vs 61%, PFS: HR:0.227
👉ICI predictive: ECOG0, no-liver mets
👉Independent to site
ESMO - Eur. Oncology

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
NatureRevClinOncol
doi.org/10.1038/s41571…
👉Comprehensive review on FGFR 🎯💊
👉Consistent efficacy & multiple approvals
👉New combinations about to come..
EASLnews ESMO - Eur. Oncology ILCA

#cholangioCA #FGFR2
Arndt Vogel c3_cholangiocarcinoma Rebecca Auer, MD
🙏recent X posts highlighting #AccessDenied #advocacy
👇open letter sent last year to provincial payers to no avail...it is our duty to advocate for our pts💚
'the inability for🇨🇦 pts ex-Quebec to access pemiganib is

MRI-guided stereotactic ablative body radiotherapy vs CT-guided percutaneous irreversible electroporation for locally advanced #PDAC
The Lancet Gastroenterology & Hepatology
doi.org/10.1016/S2468-…
🔎CROSSFIRE phs-II
👉No difference in OS
🧐Wow, interesting concepts, 'temporary DCR'...
ESMO - Eur. Oncology